Biomarkers for amyotrophic lateral sclerosis
- Detailed Technology Description
- None
- *Abstract
-
BackgroundAmyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects approximately 1 per 20,000 in the general population. There currently are no effective drug treatments and diagnosis is hindered due to the lack of definitive diagnostic tests. Therefore diagnosis typically take many months of testing to rule out all other potential causes of the initial clinical symptoms (muscle weakness is most typical).TechnologyThe inventors have identified biomarkers from the cerebral spinal fluid of patients with amyotrophic lateral sclerosis (ALS) that enables a rapid diagnosis for this neurodegenerative disease. The method involves analyzing the proteins in the sample by mass spectroscopy. The biomarker panel will also aid in clinical trials to test drug efficacy in patients.Applications1) Diagnosis of ALS2) Testing of drug efficacy in ALS patientsNon Provisional Patent Application Filed
- *Principal Investigator
-
Name: Robert Bowser
Department: Division of Neurology
Name: Srikanth Ranganathan, Graduate Student
Department: Med-Pathology
- Country/Region
- USA
For more information, please click Here
